Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BD Diagnostics Acquires Kiestra and Expands Microbiology Portfolio

By LabMedica International staff writers
Posted on 13 Mar 2012
BD Diagnostics (Franklin Lakes, NJ, USA) has acquired Kiestra (Drachtan, the Netherlands), expanding the company microbiology portfolio to include new automated instrumentation technologies, which will enable it to offer total lab automation solutions to hospitals and laboratories worldwide.

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. More...
Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery, and production of new drugs and vaccines.

Related Links:

BD Diagnostics
Kiestra



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pipette
Accumax Smart Series
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.